A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

NCT01714739 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

337

Enrollment

INDUSTRY

Sponsor class

Conditions

CANCER,NOS

Interventions

DRUG: Lirilumab
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb